Vardenafil


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Erectile dysfunction
Adult: As conventional tab: Usual dose: 10 mg as needed; may adjust according to response (range: 5-20 mg). As orodispersible tab: Max: 10 mg as needed. Dose is taken approx 25-60 minutes before sexual intercourse. Max dosing frequency: Once every 24 hours.
Elderly: As conventional tab: 5 mg as needed, at least 25-60 minutes before sexual intercourse. Max: 20 mg. Max dosing frequency: Once every 24 hours.
Special Patient Group
Patients taking α-blockers: As conventional tab: Max: 5 mg daily. As orodispersible tab: Co-administer within a 6 hour-interval.

Patient taking CYP3A4 inhibitors: As conventional tab: 2.5 mg once every 24 hours with ketoconazole 400 mg, itraconazole 400 mg, clarithromycin; 2.5 mg once every 72 hours with ritonavir; 5 mg once every 24 hours with erythromycin, ketoconazole 200 mg, itraconazole 200 mg.

Patient taking HIV-protease inhibitors: As conventional tab: 2.5 mg once every 24 hours.
Renal Impairment
CrCl (mL/min) Dosage
 <30 As conventional tab: Initially, 5 mg as needed, at least 25-60 minutes before sexual intercourse. Dose may be increased to 10-20 mg according to response.
Hepatic Impairment
Mild to moderate (Child-Pugh class A or B) As conventional tab: Initially, 5 mg as needed, at least 25-60 minutes before sexual intercourse. Max: 10 mg. Max dosing frequency: Once every 24 hours. Severe (Child-Pugh class C): Contraindicated.
Cách dùng
May be taken with or without food.
Chống chỉ định
Severe CV disorder or recent history of stroke or MI (within the last 6 months), unstable angina, retinitis pigmentosa, vision loss due to non-arteritic anterior ischaemic optic neuropathy (NAION), ESRD requiring dialysis, hypotension <90/50 mmHg, and other conditions wherein sexual intercourse is inadvisable. Severe hepatic impairment (Child-Pugh class C). Concomitant use with any form of organic nitrates/nitrites, guanylate cyclase stimulators
Thận trọng
Patient with CV disease, left ventricular outflow obstruction (aortic stenosis or hypertrophic obstructive cardiomyopathy), anatomical penile deformation, conditions which may predispose to priapism (e.g. sickle cell anaemia, multiple myeloma, leukaemia); bleeding disorders, peptic ulcer disease. Severe renal and mild to moderate hepatic impairment. Elderly. Pregnancy and lactation.
Phản ứng phụ
Significant: Hypotension, color discrimination impairment, vision loss/NAION, sudden decrease or loss of hearing, tinnitus. Rarely, prolonged/painful erection or priapism.
Gastrointestinal disorders: Dyspepsia, nausea.
General disorders and administration site conditions: Flu-like symptoms.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Nasal congestion, sinusitis.
Thông tin tư vấn bệnh nhân
This medicine may cause dizziness and blurred vision, if affected, do not drive or operate machinery.
MonitoringParameters
Assess CV status prior to initiation of therapy. Monitor BP, heart rate, renal function, and LFT.
Quá liều
Symptoms: Back pain/myalgia, abnormal vision. Management: Supportive treatment.
Tương tác
May enhance hypotensive effect of α-blockers. Increased serum concentration with guanylate cyclase stimulators (e.g. riociguat), potent CYP3A4 inhibitors (e.g. ketoconazole) and moderate CYP3A4 inhibitors (e.g. clarithromycin), HIV protease inhibitors (e.g. ritonavir). May prolong Qt interval with class IA (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) antiarrhythmics.
Potentially Fatal: Enhanced hypotensive effect with any form of organic nitrates/nitrites, guanylate cyclase stimulators (e.g. riociguat).
Food Interaction
Increased serum concentration with grapefruit juice.
Tác dụng
Description: Vardenafil is a potent phosphodiesterase inhibitor with the greatest selectivity for PDE type 5, which is responsible for the metabolism of cyclic guanosine monophosphate (cGMP) in the smooth muscle. Inhibition of PDE type 5 causes smooth muscle relaxation and increased blood flow into the corpus cavernosum of the penis during sexual stimulation, thereby producing an erection.
Onset: Approx 60 minutes.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Food, particularly high-fat meal, decreases rate of absorption. Bioavailability: Approx 15%. Time to peak plasma concentration: 0.5-2 hours.
Distribution: Widely distributed in the tissues. Volume of distribution: 208 L. Detected in the semen. Plasma protein binding: Approx 95% (parent drug and metabolite).
Metabolism: Metabolised in the liver primarily by CYP3A4 as well as CYP3A5 and CYP2C via desethylation into active metabolite.
Excretion: Mainly via faeces (approx 91-95%, as metabolites); urine (approx 2-6%). Terminal half-life: Approx 4-6 hours.
Đặc tính

Chemical Structure Image
Vardenafil

Source: National Center for Biotechnology Information. PubChem Database. Vardenafil, CID=135400189, https://pubchem.ncbi.nlm.nih.gov/compound/Vardenafil (accessed on Jan. 23, 2020)

Bảo quản
Store at 25°C.
Phân loại ATC
G04BE09 - vardenafil ; Belongs to the class of drugs used in erectile dysfunction.
References
Anon. Vardenafil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/01/2018.

Buckingham R (ed). Vardenafil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/01/2018.

Joint Formulary Committee. Vardenafil. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/01/2018.

Levitra Film Coated Tablet (GlaxoSmithKline LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 12/01/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Vardenafil từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Varafil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in